Analysis of the cutoff values in fibrin-related markers for the diagnosis of overt DIC

Clinical and Applied Thrombosis/Hemostasis

Volumn 18, Issue 5, 2012, Pages 495-500

  Hatada, Tsuyoshi ^a   Wada, Hideo ^b   Kawasugi, Kazuo ^c   Okamoto, Kohji ^d   Uchiyama, Toshimasa ^e   Kushimoto, Shigeki ^f   Seki, Yoshinobu ^g   Okamura, Takashi ^h   Imai, Hiroshi ^a   Kaneko, Toshihiro ⁱ   Nobori, Tsutomu ^b  

^a MIE UNIVERSITY HOSPITAL   (Japan)

^b MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c TEIKYO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^e NATIONAL HOSPITAL ORGANIZATION TAKASAKI GENERAL MEDICAL CENTER   (Japan)

^f NIPPON MEDICAL SCHOOL   (Japan)

^g Department of Internal Medicine   (Japan)

^h KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ MIE UNIVERSITY   (Japan)

Author keywords

D dimer; DIC; FDP; fibrin related markers (FRMs); soluble fibrin monomer complex (SFMC)

Indexed keywords

BLOOD CLOTTING FACTOR; D DIMER; FIBRIN; FIBRINOGEN DEGRADATION PRODUCT; SOLUBLE FIBRIN MONOMER COMPLEX; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; DISSEMINATED INTRAVASCULAR CLOTTING; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; SOLID TUMOR; SURVIVAL;

AGED; BIOLOGICAL MARKERS; DISSEMINATED INTRAVASCULAR COAGULATION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; HUMANS; INFECTION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84870890053     PISSN: 10760296     EISSN: 19382723     Source Type: Journal    
DOI: 10.1177/1076029611429786     Document Type: Article

References (22)

1. Wada H. Disseminated intravascular coagulation. Clin Chim Acta. 2004 ; 344 (1-2). 13-21
2. Taylor FB, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation-On behalf of the Scientific Subcommittee on disseminated intravascular coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Thromb Haemost. 2001 ; 86 (5). 1327-1330
3. Levi M, de Jonge E, van der Poll T. Sepsis and disseminated intravascular coagulation. J Thromb Thrombolysis. 2003 ; 16 (1-2). 43-47
4. Kawasugi K, Wada H, Hatada T, et al. Japanese Society of Thrombosis Hemostasis/DIC subcommittee. Prospective evaluation of hemostatic abnormalities in overt DIC due to various underlying diseases. Thromb Res. 2011 ; 128 (2). 186-190
5. Wada H, Mori Y, Shimura M, et al. Poor outcome in disseminated intravascular coagulation or thrombotic thrombocytopenic purpura patients with severe vascular endothelial cell injuries. Am J Heamtol. 1998 ; 58 (3). 189-194
6. Asakura H, Wada H, Okamoto K, et al. Evaluation of hemostatic molecular markers for diagnosis of disseminated intravascular coagulation in patients with infections. Thromb Haemost. 2006 ; 95 (2). 282-287
7. Wada H, Asakura H, Okamoto K, et al. Japanese Society of Thrombosis Hemostasis/ DIC subcommittee. Expert consensus for the treatment of disseminated intravascular coagulation in Japan. Thromb Res. 2010 ; 125 (1). 6-11
8. Wada H, Nagano T, Tomeoku M, et al. Coagulant and fibrinolytic activities in the leukemic cell lysates. Thromb Res. 1982 ; 30 (4). 315-322
9. Wada H, Kumeda Y, Ogasawara Z, et al. Plasminogen activators and their inhibitors in leukemic cell homogenates. Am J Hematol. 1993 ; 42 (2). 166-170
10. Kobayashi N, Maegawa T, Takada M, Tanaka H, Gonmori H. Criteria for diagnosis of DIC based on the analysis of clinical and laboratory findings in 345 DIC patients collected by the Research Committee on DIC in Japan. Bibl Haemotol. 1987 ; 49: 265-275
11. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost. 1996 ; 75 (2). 224-228
12. Wada H, Yamamuro M, Inoue A, et al. Comparison of the responses of global tests of coagulation with molecular markers of neutrophil, endothelial, and hemostatic system perturbation in the baboon model of E. coli sepsis-toward a distinct between uncompensated overt DIC and compensated non-overt DIC. Thromb Haemost. 2001 ; 86 (6). 1489-1494
13. Asakura H, Ontachi Y, Mizutani T, et al. Decreased plasma activity of antithrombin or protein C is not due to consumption coagulopathy in septic patients with disseminated intravascular coagulation. Eur J Haematol. 2001 ; 67: 170-175
14. Wada H, Sase T, Matsumoto T, et al. Increased soluble fibrin in plasma from disseminated intravascular coagulation. Clin Appl Thromb Haemost. 2003 ; 9 (3). 233-240
15. Smalberg JH, Kruip MJ, Janssen HL, Rijken DC, Leebeek FW, de Maat MP. Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: similarities and differences. Arterioscler Thromb Vasc Biol. 2011 ; 31 (3). 485-493
16. Rhee J, Han SW, Oh DY, Im SA, Kim TY, Bang YJ. Clinicopathologic features and clinical outcomes of gastric cancer that initially presents with disseminated intravascular coagulation: a retrospective study. J Gastroenterol Hepatol. 2010 ; 25 (9). 1537-1542
17. Wada H, Kobayashi T, Abe Y, et al. Elevated levels of soluble fibrin or d-dimer indicate high risk of thrombosis. J Thromb Haemost. 2006 ; 4 (6). 1253-1258
18. Dhainaut JF, Yan SB, Joyce DE, et al. Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation. J Thromb Haemost. 2004 ; 2 (11). 1924-1933
19. Dempfle CE. Coagulopathy of sepsis. Thromb Haemost. 2004 ; 91 (2). 213-224
20. Wada H, Gabazza EC, Asakura H, et al. Comparison of diagnostic criteria for disseminated intravascular coagulation (DIC): diagnostic criteria of the International Society of Thrombosis and Haemostasis (ISTH) and of the Japanese Ministry of Health and Welfare for overt-DIC. Am J Hematol. 2003 ; 74 (1). 17-22
21. Bernard GR, Vincent JL, Laterre PF, et al. Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human protein C for severe sepsis. N Engl J Med. 2001 ; 344 (10). 699-709
22. Kienast J, Juers M, Wiedermann CJ, et al. KyberSept investigators. Treatment effects of high-dose antithrombin without concomitant heparin in patients with severe sepsis with or without disseminated intravascular coagulation. J Thromb Haemost. 2006 ; 4 (1). 90-97